1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Liver conditions
  5. Alcohol-use disorders

Rifaximin for preventing episodes of overt hepatic encephalopathy

Technology appraisal guidance [TA337] Published: 25 March 2015

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The company's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Review of guidance
  • 7 Appraisal Committee members and NICE project team
  • 8 Sources of evidence considered by the Committee
  • About this guidance
Download guidance (PDF)

Guidance

  • Next

1 Guidance

1 Guidance

1.1 Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in people aged 18 years or older.

  • National Institute for Health and Care Excellence (NICE)

  • Next